Advertisement

Colchicine in Pericardial Disease: from the Underlying Biology and Clinical Benefits to the Drug-Drug Interactions in Cardiovascular Medicine

  • Aldo L. Schenone
  • Venu Menon
Pericardial Disease (AL Klein, Section Editor)
  • 231 Downloads
Part of the following topical collections:
  1. Topical Collection on Pericardial Disease

Abstract

Purpose of Review

This is an in-depth review on the mechanism of action, clinical utility, and drug-drug interactions of colchicine in the management of pericardial disease.

Recent Findings

Recent evidence about therapeutic targets on pericarditis has demonstrated that NALP3 inflammasome blockade is the cornerstone in the clinical benefits of colchicine. Such benefits extend from acute and recurrent pericarditis to transient constriction and post-pericardiotomy syndrome. Despite the increased utilization of colchicine in cardiovascular medicine, safety concerns remains unsolved regarding the long-term use of colchicine in the cardiac patient. Moreover, recent evidence has demonstrated that numerous cardiovascular medications, ranging from antihypertensive medication to antiarrhythmics, are known to interact with the CYP3A4 and/or P-gp system increasing the toxicity potential of colchicine.

Summary

The use of adjunctive colchicine in the management of inflammatory pericardial diseases is standard of care in current practice. It is advised that a careful medication reconciliation with emphasis on pharmacokinetic is completed before prescribing colchicine in order to avoid harmful interaction by finding an alternative regimen or adjusting colchicine dosing.

Keywords

Colchicine Pericardial disease Toxicity Drug interactions 

Notes

Author’s Contributions

Aldo L. Schenone and Venu Menon contributed substantially to the conception and design of the work. Both authors were responsible for drafting and key revisions to this manuscript. Both authors have approved the final version of the manuscript and are accountable for all aspects related to the accuracy or integrity of this manuscript.

Compliance with Ethical Standards

Conflict of Interest

Both authors involved with this manuscript have no financial or personal relationships with other people or organizations that could inappropriately influence or bias their work. Therefore, Aldo L. Schenone and Venu Menon have no conflicts of interest that might be relevant to the contents of this manuscript.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    LeWinter MM. Acute pericarditis. N Engl J Med. 2014;371:2410–6.CrossRefPubMedGoogle Scholar
  2. 2.
    • Cremer PC, Kumar A, Kontzias A, Tan CD, Rodriguez ER, Imazio M, et al. Complicated pericarditis. J Am Coll Cardiol. 2016;68:2311–28. This study provides a thorough review on the pathophysiology and modern management of pericarditis. CrossRefPubMedGoogle Scholar
  3. 3.
    Imazio M, Brucato A, Cemin R, Ferrua S, Maggiolini S, Beqaraj F, et al. A randomized trial of colchicine for acute pericarditis. N Engl J Med. 2013;369:1522–8.CrossRefPubMedGoogle Scholar
  4. 4.
    Chen K, Schenone A, Borges N, et al. Teaching an old dog new tricks: colchicine in cardiovascular medicine. Am J Cardiovasc Drugs. Google Scholar
  5. 5.
    •• Leung YY, Yao Hui LL, Kraus VB. Colchicine—update on mechanisms of action and therapeutic uses. Semin Arthritis Rheum. 2015;45:341–50. This study provides a thorough review on the pharmacokinetics and pharcodynamics of colchicine. CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Syed FF, Schaff HV, Oh JK. Constrictive pericarditis—a curable diastolic heart failure. Nat Rev Cardiol. 2014;11:530–44.CrossRefPubMedGoogle Scholar
  7. 7.
    Fernandes F, Ramires FJA, Ianni BM, Salemi VMC, Oliveira AM, Pessoa FG, et al. Effect of colchicine on myocardial injury induced by Trypanosoma cruzi in experimental chagas disease. J Card Fail. 2012;18:654–9.CrossRefPubMedGoogle Scholar
  8. 8.
    • Xu B, Harb SC, Cremer PC. New insights into pericarditis: mechanisms of injury and therapeutic targets. Curr Cardiol Rep. 19  https://doi.org/10.1007/s11886-017-0866-6. This study provides a thorough review on the therapeutic targets in pericarditis.
  9. 9.
    Imazio M. Idiopathic recurrent pericarditis as an immune-mediated disease: current insights into pathogenesis and emerging treatment options. Expert Rev Clin Immunol. 2014;10:1487–92.CrossRefPubMedGoogle Scholar
  10. 10.
    Cusick MF, Libbey JE, Fujinami RS. Molecular mimicry as a mechanism of autoimmune disease. Clin Rev Allergy Immunol. 2012;42:102–11.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Sfriso P, Ghirardello A, Botsios C, Tonon M, Zen M, Bassi N, et al. Infections and autoimmunity: the multifaceted relationship. J Leukoc Biol. 2010;87:385–95.CrossRefPubMedGoogle Scholar
  12. 12.
    Dauphin C, E M, A C, et al. Recurrent pericarditis: current challenges and future prospects. Res Rep Clin Cardiol. 2016;7:99–108.Google Scholar
  13. 13.
    Rodirguez de la Serna A, Guindo Soldevilla J, Marti Claramunt V, et al. Colchicine for recurrent pericarditis. Lancet. 1987;330:1517.CrossRefGoogle Scholar
  14. 14.
    Adler Y, Finkelstein Y, Guindo J, Rodriguez de la Serna A, Shoenfeld Y, Bayes-Genis A, et al. Colchicine treatment for recurrent pericarditis. A decade of experience. Circulation. 1998;97:2183–5.CrossRefPubMedGoogle Scholar
  15. 15.
    Adler Y, Charron P, Imazio M, Badano L, Barón-Esquivias G, Bogaert J, et al. 2015 ESC guidelines for the diagnosis and management of pericardial diseases. Eur Heart J. 2015;36:2921–64.CrossRefPubMedGoogle Scholar
  16. 16.
    Imazio M, Bobbio M, Cecchi E, Demarie D, Demichelis B, Pomari F, et al. Colchicine in addition to conventional therapy for acute pericarditis: results of the Colchicine for acute Pericarditis (COPE) trial. Circulation. 2005;112:2012–6.CrossRefPubMedGoogle Scholar
  17. 17.
    Imazio M, Belli R, Brucato A, Cemin R, Ferrua S, Beqaraj F, et al. Efficacy and safety of colchicine for treatment of multiple recurrences of pericarditis (CORP-2): a multicentre, double-blind, placebo-controlled, randomised trial. Lancet. 2014;383:2232–7.CrossRefPubMedGoogle Scholar
  18. 18.
    Imazio M, Brucato A, Cemin R, Ferrua S, Belli R, Maestroni S, et al. Colchicine for recurrent pericarditis (CORP): a randomized trial. Ann Intern Med. 2011;155:409–14.CrossRefPubMedGoogle Scholar
  19. 19.
    Imazio M, Bobbio M, Cecchi E, Demarie D, Pomari F, Moratti M, et al. Colchicine as first-choice therapy for recurrent pericarditis: results of the CORE (Colchicine for Recurrent pericarditis) trial. Arch Intern Med. 2005;165:1987–91.CrossRefPubMedGoogle Scholar
  20. 20.
    Meurin P, Lelay-Kubas S, Pierre B, Pereira H, Pavy B, Iliou MC, et al. Colchicine for postoperative pericardial effusion: a multicentre, double-blind, randomised controlled trial. Heart. 2015;101:1711–6.CrossRefPubMedGoogle Scholar
  21. 21.
    Izadi Amoli A, Bozorgi A, HajHossein Talasaz A, Salehi Omran A, Mortazavi SH, Jalali A, et al. Efficacy of colchicine versus placebo for the treatment of pericardial effusion after open-heart surgery: a randomized, placebo-controlled trial. Am Heart J. 2015;170:1195–201.CrossRefPubMedGoogle Scholar
  22. 22.
    Gunda S, Reddy M, Nath J, et al. Impact of periprocedural colchicine on postprocedural management in patients undergoing a left atrial appendage ligation using LARIAT. J Cardiovasc Electrophysiol. 2016;27:60–4.CrossRefPubMedGoogle Scholar
  23. 23.
    Colcrys (colchicine) US prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022351lbl.pdf (2011, accessed 23 January 2018).
  24. 24.
    Slobodnick A, Shah B, Pillinger MH, Krasnokutsky S. Colchicine: old and new. Am J Med. 2015;128:461–70.CrossRefPubMedGoogle Scholar
  25. 25.
    Imazio M, Brucato A, Ferrazzi P, Rovere ME, Gandino A, Cemin R, et al. Colchicine reduces postoperative atrial fibrillation: results of the Colchicine for the Prevention of the Postpericardiotomy Syndrome (COPPS) atrial fibrillation substudy. Circulation. 2011;124:2290–5.CrossRefPubMedGoogle Scholar
  26. 26.
    Cremer PC, Tariq MU, Karwa A, Alraies MC, Benatti R, Schuster A, Agarwal S, Flamm SD, Kwon DH, Klein AL Quantitative assessment of pericardial delayed hyperenhancement predicts clinical improvement in patients with constrictive pericarditis treated with anti-inflammatory therapy. Circ Cardiovasc Imaging 8.  https://doi.org/10.1161/CIRCIMAGING.114.003125.
  27. 27.
    Feng D, Glockner J, Kim K, Martinez M, Syed IS, Araoz P, et al. Cardiac magnetic resonance imaging pericardial late gadolinium enhancement and elevated inflammatory markers can predict the reversibility of constrictive pericarditis after antiinflammatory medical therapy: a pilot study. Circulation. 2011;124:1830–7.CrossRefPubMedGoogle Scholar
  28. 28.
    Aviv M, Yeela T, Chezar AC, et al. Does colchicine decrease the rate of recurrence of acute idiopathic pericarditis treated with glucocorticoids? J Cardiol.  https://doi.org/10.1016/j.jjcc.2017.10.005.
  29. 29.
    Finkelstein Y, Shemesh J, Mahlab K, Abramov D, Bar-El Y, Sagie A, et al. Colchicine for the prevention of postpericardiotomy syndrome. Herz. 2002;27:791–4.CrossRefPubMedGoogle Scholar
  30. 30.
    Imazio M, Brucato A, Ferrazzi P, Pullara A, Adler Y, Barosi A, et al. Colchicine for prevention of postpericardiotomy syndrome and postoperative atrial fibrillation: the COPPS-2 randomized clinical trial. Jama. 2014;312:1016–23.CrossRefPubMedGoogle Scholar
  31. 31.
    Papageorgiou N, Briasoulis A, Lazaros G, Imazio M, Tousoulis D. Colchicine for prevention and treatment of cardiac diseases: a meta-analysis. Cardiovasc Ther. 2017;35:10–8.CrossRefPubMedGoogle Scholar
  32. 32.
    Solak Y, Siriopol D, Yildiz A, Yilmaz MI, Ortiz A, Covic A, et al. Colchicine in renal medicine: new virtues of an ancient friend. Blood Purif. 2017;43:125–35.CrossRefPubMedGoogle Scholar
  33. 33.
    FDA/Center for Drug Evaluation and Research. Colchicine Medical Reviews https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022351s000_SumR.pdf (2008).
  34. 34.
    Davis MW, Wason S. Effect of steady-state atorvastatin on the pharmacokinetics of a single dose of colchicine in healthy adults under fasted conditions. Clin Drug Investig 34.Google Scholar
  35. 35.
    Alayli G, Cengiz K, Cantürk F, Durmuş D, Akyol Y, Menekşe EB. Acute myopathy in a patient with concomitant use of pravastatin and colchicine. Ann Pharmacother. 2005;39:1358–61.CrossRefPubMedGoogle Scholar
  36. 36.
    Verma S, Eikelboom JW, Nidorf SM, al-Omran M, Gupta N, Teoh H, et al. Colchicine in cardiac disease: a systematic review and meta-analysis of randomized controlled trials. BMC Cardiovasc Disord. 2015;15:96.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    •• Wessler JD, Grip LT, Mendell J, Giugliano RP. The P-glycoprotein transport system and cardiovascular drugs. J Am Coll Cardiol. 2013;61:2495–502. This study provides extensive data on interaction of numerous cardiovascular drug with the P-gp system. CrossRefPubMedGoogle Scholar
  38. 38.
    •• Wiggins BS, Saseen JJ, Page RL, et al. Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2016;134:e468–95. This consensus document provides clinically relevant data on the coadministration of colchicine and statin. CrossRefPubMedGoogle Scholar
  39. 39.
    Fujino H, Saito T, Ogawa S, Kojima J. Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase. J Pharm Pharmacol. 2005;57:1305–11.CrossRefPubMedGoogle Scholar
  40. 40.
    •• Terkeltaub RA, Furst DE, Digiacinto JL, et al. Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P-glycoprotein inhibitors. Arthritis Rheum. 2011;63:2226–37. This study provides colchicine dosing recommendation for concomitant therapy with CYP3A4 and P-gp inhibitors. CrossRefPubMedGoogle Scholar
  41. 41.
    Zisaki A, Miskovic L, Hatzimanikatis V. Antihypertensive drugs metabolism: an update to pharmacokinetic profiles and computational approaches. Curr Pharm Des. 2015;21:806–22.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Flockhart D, Tanus-Santos J. Implications of cytochrome P450 interactions when prescribing medication for hypertension. Arch Intern Med. 2002;162:405–12.CrossRefPubMedGoogle Scholar
  43. 43.
    Yamreudeewong W, DeBisschop M, Martin LG, Lower DL. Potentially significant drug interactions of class III antiarrhythmic drugs. Drug Saf. 2003;26:421–38.CrossRefPubMedGoogle Scholar
  44. 44.
    Lynch T, Price A. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am Fam Physician. 2007;76:391–6.PubMedGoogle Scholar
  45. 45.
    Ehrhardt M, Lindenmaier H, Burhenne J, Haefeli WE, Weiss J. Influence of lipid lowering fibrates on P-glycoprotein activity in vitro. Biochem Pharmacol. 2004;67:285–92.CrossRefPubMedGoogle Scholar
  46. 46.
    Hemkens Lars G, Ewald H, Gloy Viktoria L, et al. Colchicine for prevention of cardiovascular events. Cochrane Database Syst Rev.  https://doi.org/10.1002/14651858.CD011047.pub2.

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Cardiovascular MedicineCleveland ClinicClevelandUSA

Personalised recommendations